Johnson & Johnson will pay up to $5.5 billion to settle roughly 76,000 lawsuits alleging its baby powder caused ovarian cancer — a fraction of what the company earned selling talc products to American families for decades, and a price that comes with zero criminal liability for any executive involved.

The settlement, announced Monday, covers nearly all remaining claims from women who say J&J's talc-based products — contaminated with asbestos, according to plaintiffs — gave them cancer. The deal requires 95% of claimants to opt in. J&J will pay $3 billion in 2027 and the rest after 2028. Plaintiffs' attorney Chris Seeger, who represents about 2,500 clients, said the total could exceed $7 billion because the payout is uncapped. "We got a fair settlement, and our clients are going to be happy with it," Seeger told the New York Post.

J&J's vice president of litigation, Erik Haas, called the claims "meritless" — the same word the company has used for 15 years while fighting these cases. "While we are confident the company would have ultimately prevailed with further litigation, as it has in the vast majority of cases tried to date, this resolution allows the company to put this matter behind it," Haas said in a statement. CNN noted that J&J has called some verdicts against it "egregious and unconstitutional" — quite the posture from a company accused of poisoning its own customers.

The timing is no accident. Last week, a federal judge cast doubt on roughly 69,000 claims, ordering plaintiffs to produce specific evidence linking their cancer to J&J's products. ABC News reported that Haas said the court's order put plaintiffs in "an untenable position" because the specific causation evidence "does not exist." The settlement came days later — leverage achieved, discount locked in.

Then there's the "Texas two-step." J&J spent more than three years trying to offload liability into a shell-company subsidiary, filing three bankruptcies to force a settlement on the cheap. Every one was dismissed. The litigation only resumed in March 2025 after that gambit collapsed, according to the Guardian and the Post.

J&J pulled talc-based baby powder from North America in 2020 and went global with cornstarch in 2023, claiming it was just simplifying its product line — not reacting to the cancer allegations it still denies. Last October, a Los Angeles jury ordered J&J to pay $966 million to the family of a woman who died of mesothelioma from asbestos exposure. The company said it would appeal.

Wall Street liked the deal. Shares rose more than 2% before market open, per ABC News. For a company that generated $85 billion in revenue last year, $5.5 billion spread over years is a line item — not a punishment. And critically, the settlement only covers existing claims. Anyone who gets sick tomorrow is on their own.

No J&J executive will face a courtroom dock. No one will wear handcuffs for selling a product the company quietly pulled from shelves while insisting it was safe. The fine print of this deal ensures the past gets buried and the future stays open.

The question isn't whether $5.5 billion is enough for 76,000 cancer victims. The question is why the people who made the decision to keep selling that powder are still walking free — and whether any corporation will ever face a penalty that actually costs more than the crime.